Working… Menu
Trial record 5 of 14 for:    glutamate antagonist | Parkinson Disease

Parkinson's Disease Evaluated by PET and the Effect of Memantine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00375778
Recruitment Status : Completed
First Posted : September 13, 2006
Last Update Posted : September 13, 2006
Lundbeck Foundation
Information provided by:
University of Aarhus

Brief Summary:

Purpose of study: To investigate whether the NMDA antagonist Memantine has a substantial effect of brain metabolism in patients with Parkinson's disease (PD), using Positron Emission Tomography (PET).

Background: Disturbances in brain metabolism is thought to contribute to degeneration of neurons in brain of PD patients. Production of toxic oxygen radicals and presence of too much excitatory neurotransmitter (glutamate) due to over activity is involved. These factors can theoretically be alleviated by memantine.

Hypothesis: Memantine decreases metabolism in areas in PD brain known to be over-active. Decreases in cerebral blood flow and oxygen metabolism in these areas will be the consequence and this can be detected by PET.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: memantine (drug) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine
Study Start Date : April 2005
Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Parkinson's Disease (British Brain Bank Criteria)
  • Age 50-70y

Exclusion Criteria:

  • Tobacco use
  • Any serious medical conditions (Heart disease, kidney disease, liver disease, endocrinological disorders etc)
  • Metal implants contraindicating MR scan
  • Drug use affecting the central nervous system
  • Psychiatric disorders
  • Head trauma or any disorders of the head, skull or brain
  • Drug addiction or use of any kind of illegal substance affecting the central nervous system
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00375778

Layout table for location information
PET center, Aarhus University Hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Lundbeck Foundation
Layout table for investigator information
Principal Investigator: Karen Ostergaard, MD, Ph.D Aarhus University Hospital
Layout table for additonal information Identifier: NCT00375778    
Other Study ID Numbers: 2004-004139-74
First Posted: September 13, 2006    Key Record Dates
Last Update Posted: September 13, 2006
Last Verified: September 2006
Keywords provided by University of Aarhus:
Parkinson's Disease
Positron Emission Tomography
NMDA antagonists
Cerebral Blood Flow
Cerebral Metabolic Rate of Oxygen
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Excitatory Amino Acid Antagonists
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Agents